Brolucizumab-dbll

This policy covers intravitreal brolucizumab‑dbll (Beovu®) anti‑VEGF therapy for retinal neovascular conditions including neovascular (wet) AMD, diabetic macular edema, choroidal neovascularization (including myopic CNV) and related CNV indications, as well as uveitis. Coverage is limited to HCSC Ohio members whose benefit plan includes prescription drug coverage and generally requires prior intravitreal bevacizumab trial/failure (unless contraindicated or there is a documented shortage/recall), dosing per authoritative sources, documented clinical benefit for continuation, and off‑label uses must be supported by compendia or two peer‑reviewed articles.

"Coverage of any FDA‑approved drug when prescribed for a use recognized as safe and effective in one or more standard medical reference compendia adopted by the U."

Sign up to see full coverage criteria, indications, and limitations.